



December 6, 2005

**The Shareholders of Can-Fite BioPharma will be Requested
to Approve the Appointment of Dr. Itzhak Krinsky, Vice
President in Teva Pharmaceutical Industries and Prof.
Yechezkel Barenholz from the Hebrew University as
External Directors in the Company**

Can-Fite's Board of Directors has recently decided to recommend to the shareholders of the company to approve the appointment of Dr. Itzhak Krinsky, Vice President for Business Development in Teva and Prof. Yechezkel Barenholz, world renowned scientist from the Hebrew University of Jerusalem, as external directors in the company. The shareholder's meeting will take place on December 22, 2005.

Dr. Itzhak Krinsky has extensive business development experience in the pharmaceutical field, which he acquired in his role in Teva as well as from his previous many years of investment banking experience, including as Managing Director in the Mergers and Acquisitions group and a member of the Technology M&A and M&A Strategies Teams at Deutsche Banc Alex Brown in New York. Dr. Krinsky has a B.A. and M.A. from Tel Aviv University and has a Ph.D. from McMaster University, Canada. He also served in the past as Professor of Finance & Business Economics in the McMaster University, Canada and has published extensively in this field.

Prof. Barenholz is a Professor of Biochemistry and Daniel G. Miller Professor in Cancer Research and is the Head of Laboratory of Membrane and Liposome Research, Department of Biochemistry, in the Medical School of the Hebrew University of Jerusalem. Prof. Barenholz gained worldwide fame as a result of his research in biological membranes as well as from his applied research focused on the use of different kinds of liposomes as drug delivery vehicles and is one of the leading scientists in this field. One of the inventions in which he was involved was the basis of DOXIL®, a drug sold throughout the World by Johnson & Johnson, Inc. with annual sales of ABOUT US\$ 400 million. Prof. Barenholz has authored about 300 scientific manuscripts and is a member of the editorial board of a number of important scientific journals. He is also an inventor in many patents and patent applications and a few of his inventions are the technology foundation for emerging and other companies.

Prof. Fishman, the company's CEO, expressed her great satisfaction from the Board's decision and noted that the company will undoubtedly greatly benefit from the vast experience and knowledge that will be brought by Dr. Krinsky and Prof. Barenholz.

About Can-Fite

Can-Fite BioPharma Ltd. is a public company, traded on the Tel-Aviv Stock Exchange that is headquartered in Petach-Tikva, Israel. The company, which began its operations at the end of 2000 was founded based on the work by Professor Pnina Fishman, formerly a Tumor Immunologist in the Rabin Medical Center and currently the company's CEO, together with Dr Ilan Cohn, Patent Attorney and Senior Partner at Reinhold Cohn and Partners, a leading Israeli Patent Attorney firm. The Company has research laboratories and offices in Israel. The Company's lead drug, CF101, for the treatment of rheumatoid arthritis is currently in Phase II clinical trials and to date went through clinical trials in the USA, UK and Israel.

About CF101

CF101 is a small molecule, which is administered to patients orally. This drug, which is developed for the treatment of rheumatoid arthritis, was tested to date in clinical trials in the USA, UK and Israel. The drug is active against a wide variety of autoimmune and cancer diseases and has a preferential safety profile. The drug's main advantage is in its ability to specifically attack pathological cells without affecting healthy ones. In addition, the fact that the drug is administered orally in the form of a capsule creates a huge advantage vs. current treatments which are administered by IV infusion or injection, at much higher costs. The annual potential market for the treatment of rheumatoid arthritis is currently about US\$ 5 billion and is expected to rise at an annual rate of about 20%.

More information visit www.canfite.com or call Prof. Pnina Fishman at 03-9241114

Respectfully,

Tali Saar – 052-2807771
Financial Communication
148 Menahem Begin Rd..
Tel Aviv 64921
Tel: (972) 36954-333
Fax: (972) 3695-32-32
TALIS15@BEZEQINT.NET